IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.519
EU - Europa 5.465
AS - Asia 2.087
Continente sconosciuto - Info sul continente non disponibili 19
SA - Sud America 10
AF - Africa 9
OC - Oceania 4
Totale 14.113
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.505
CN - Cina 1.162
IE - Irlanda 1.094
UA - Ucraina 965
SE - Svezia 797
FR - Francia 723
IT - Italia 688
TR - Turchia 642
GB - Regno Unito 596
DE - Germania 319
IN - India 184
FI - Finlandia 140
VN - Vietnam 70
BE - Belgio 48
AT - Austria 32
EU - Europa 19
PL - Polonia 10
RU - Federazione Russa 10
CA - Canada 9
IL - Israele 6
NL - Olanda 6
SG - Singapore 6
EG - Egitto 5
AU - Australia 4
BR - Brasile 4
CH - Svizzera 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
GR - Grecia 4
ID - Indonesia 4
MX - Messico 4
RO - Romania 4
CL - Cile 3
ES - Italia 3
HR - Croazia 3
IR - Iran 3
JP - Giappone 3
HK - Hong Kong 2
LT - Lituania 2
PY - Paraguay 2
AM - Armenia 1
BG - Bulgaria 1
BS - Bahamas 1
DZ - Algeria 1
EE - Estonia 1
HU - Ungheria 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 14.113
Salva come PNG Salva come JPEG
Città #
Chandler 1.589
Jacksonville 1.249
Dublin 1.084
Princeton 496
Southend 456
Izmir 390
Nanjing 361
Ashburn 289
Wilmington 242
Beijing 225
Dearborn 189
Cambridge 186
Ann Arbor 180
Altamura 174
Chieti 138
Boardman 136
Nanchang 132
Woodbridge 97
Houston 82
New York 81
Dong Ket 69
Shenyang 64
Hebei 63
Kunming 56
Tianjin 52
Brussels 48
Los Angeles 48
Washington 45
Jiaxing 44
Norwalk 39
Vienna 32
Falls Church 28
Changsha 25
Hangzhou 22
Kocaeli 20
Rome 20
Seattle 20
Lanzhou 17
San Mateo 17
Auburn Hills 16
Pescara 15
Grevenbroich 14
Tappahannock 14
Augusta 13
Changchun 13
Edinburgh 13
Guangzhou 11
Leawood 11
Ningbo 11
Düsseldorf 10
Frontone 10
Chicago 9
Jinan 9
London 9
Fairfield 8
Giaveno 8
Milan 8
Aprilia 7
Hefei 7
Helsinki 7
Shanghai 7
Zhengzhou 7
Collecorvino 6
Giulianova 6
Menlo Park 6
Orange 6
Redwood City 6
Cairo 5
Monmouth Junction 5
Mumbai 5
Pune 5
Amsterdam 4
Anzio 4
Denver 4
Napoli 4
Paris 4
Shaoxing 4
Spoltore 4
Toronto 4
Altino 3
Ameno 3
Ardabil 3
Avellino 3
Copenhagen 3
Francavilla al Mare 3
Haikou 3
Hanover 3
Jinhua 3
Keputih 3
L'aquila 3
Leicester 3
Mexico City 3
Montreal 3
Munich 3
Penne 3
Rossano Veneto 3
San Vito Chietino 3
Santa Clara 3
Savigliano 3
Simi Valley 3
Totale 8.887
Salva come PNG Salva come JPEG
Nome #
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 105
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 103
A multidisciplinary group for prostate cancer management: A single institution experience 102
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 101
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 95
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 94
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 93
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 92
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 91
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 91
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 91
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 91
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 91
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 89
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 87
90K (Mac-2 BP) in human milk 84
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 84
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 84
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 83
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 82
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 82
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 82
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 81
Chemotherapy preoperative for the management of breast cancer locally advanced 81
Unknown primary tumors 80
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 80
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 80
Principali effetti collaterali delle terapie mediche 80
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 79
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 79
null 79
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 78
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 78
A phase I study of 5-day continuous venous infusion of carboplatin at circadian rhythm-modulated rate compared with constant rate 77
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 77
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery 77
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 77
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 77
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 77
Surgical treatment of adrenal metastases from non small cell lung cancer 76
null 76
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 75
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 75
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 75
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 75
A phase I study of 5-day continuous venous infusion of carboplatin at circadian rhythm-modulated rate compared with constant rate. 74
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 74
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 74
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 74
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 73
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 73
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 73
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 73
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 73
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 73
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 72
Prognostic value of a novel circulating serum 90K antigen in breast cancer 72
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 72
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 72
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 72
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 72
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 71
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 71
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 71
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 71
Prognostic value of 90K protein in HIV infection 70
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 70
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 70
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 69
null 69
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 69
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 69
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis 69
La stimolazione dinamica con IFN-α per la diagnosi precoce di ripresa di malattia in pazienti NED 68
DNA ploidy and S-phase fraction in pulmonary carcinoids. 68
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 68
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 68
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 67
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 67
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 67
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 67
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 66
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 66
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 66
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 66
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 66
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 65
CYLOOXYGENASE-INDEPENDENT INDUCTION OF THE TUMOR SUPPRESSOR PROTEIN P21WAF-1/CIP1 AND DIFFERENTIATION BY L-745,337, A SELECTIVE COX-2 INHIBITOR, AND SODIUM SALICYLATE, IN HT-29 COLON CANCER CELLS. 65
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 65
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. 65
Rivaroxaban for cancer-associated cardiac thrombosis 65
Tyrosine kinase inhibitors 65
null 65
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 65
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 65
Combined therapy in pancreatic cancer 64
BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF CYCLOOXYGENASE ACTIVITY OF HUMAN BLOOD PROSTAGLANDIN ENDOPEROXIDE SYNTHASES. 64
A Flow cytometric study of early gastric cancer 64
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 64
Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies? 64
Totale 7.566
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.211
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019543 0 0 0 0 0 0 0 0 0 33 22 488
2019/20203.222 1.025 181 40 114 257 210 320 236 178 288 345 28
2020/20211.539 240 24 294 14 96 305 36 43 100 161 92 134
2021/20221.154 23 33 9 200 119 28 24 72 83 28 143 392
2022/20234.117 332 500 287 502 417 769 214 346 477 39 143 91
2023/20241.533 137 58 123 54 133 593 310 50 25 50 0 0
Totale 14.964